
# Detecting Tumor Mutational Signatures with a CNN

Beth Baumann, Metis Final Project, Fall 2020


#### Types of single nucleotide variants (SNVs) and indels




Variant: Occurs in healthy human population

Mutation: Occurs in tumor, but not common in healthy population

#### What are Mutational Signatures?



#### **Project Goals and Applications**





**Train** a neural network to identify a tumor type from short aligned DNA sequences




**Discover** mutational signatures and insights about tumor types



**Predict** tumor origin of sequencing reads from liquid biopsy (if model well-developed with a high F1 score)

#### Generating synthetic but realistic 100bp exome sequencing read alignments



#### What signatures can a Convolutional Neural Network learn about?

#### **SNVs** in context


Learn variable lengths of context

#### Indels of any length

Learn variable indel length

#### **Specific Mutations**

Learn frequent specific mutation and hot spot sequences



### Important Nearby Sequence


Ex. protein binding sites, microhomology domains

## No: Structural and Copy Number Variants

Too long for this method

## No: Mutational Load

Method only looks at mutations in isolation




#### Where is the CNN placing importance for classification?

ACGGAGAATTTATCCATCAGATTTTGCCGTGGAGATACTTTTTTGGCGAGAAAATGACTTCCAGTGATGTTGTAGCTGGATCCGATTAAGTATAGCTCCCC ACGAAGAATTTATTCATCAGATTTTGCCGTGGAGATACTTTTTGGCGAGAAAATGACTTCCAGTGATGTTGTAGCTGAATCCAATTAAGTATAGCTCCTC TTTCCTTTAGGCAGAGGTCTATGAACACCTTCAAGGGCTGGCGCTCTCCCATCCTTGGACAGTCCTCCACTGTCTGCCTCTTACTCATGGCCTCTGGGGA TTTTCTTTAGGCAGAGGTCTATGAACACCTTCAAGGGCTGGCGCTCTCCCATCCTTGGACAGTCCTCCACTGTCTGCCTTTTACTCATAACCTCTGGGGA CCTGTTCCACTAATTTTCCTGAGGCTAATTCCTCTTGGAGTTTC<mark>TGAA</mark>CTTTCAATGTTCGTTTTGCCTTTAAAAAAAXXXXXXXXXGAA<mark>AAAAAAAAAAA</mark>A CTTCTCCCCAGTATGAATTATCTTATGTTTAGTAAGGGCTGAAAGATGGTTAAAAGCTTTGCCACATTCTTCACATTTGTAGGTTTTCCCTCCAGTATGA CTTCTTTCCAGTATGAATTATCTTATGTTTAGTAAGGGCTGAAAAATGGTTAAAAGCTTTGCCACATTCTTCACATTTGTAGGGTTTTCCTCCAGTATGA rccatccgcaga<mark>gcag</mark>agcagtgggaggaga<mark>cgct</mark>atgacccccatcctcacagtcctgatctgtctcggtgagatttgaagagggagaagagcttcta CTTGGTCTAATTGTTCTCATCTGGAAAGACCCTCACCTTCATATCCCAATGTACTT<mark>ATTCCTTGGGAGTTTAGCCTT</mark>TGTGGAT<mark>GCTT</mark>CGTTATCA<mark>TCCA</mark> CTTGGTCTAATTGTTCTCATCTGGAAAGACCCTCACCTTCATATCCCAATGTACTT<mark>ATTCTTTTGGAAG</mark>TTTAGCTTTTGTGGATGCTT<mark>T</mark>GTTATCA<mark>TCTA</mark> AGACGTTAATCACGTTTCATGCATCTCCAATCATCATGTTCTAATCTGCCCTCCGGAGGAGGAACAGGTAAGGATTATCCCACCTGACGATACAGACXXX AGACGTTAATCACGTTTCATACATCTCCAATCATCATATCCTAATCTGTCCTC<mark>CAAAGAAA</mark>GAACAAGTAAGGATTATCCCACTTGACAATACAAGCAAA AGACGTTAATCACGTTTCATGCATCTCCAATCATCATGTTCTAATCTGCCCTCCGGAGGAGGACAGGTAAGGATTATCCCACCTGACGATACAGACXXX GCAGTGGCTGCA<mark>GGAAGTCACAGAAGGGCAGGACCTGAACGCTGTCTGCTTTT</mark>CTGGAATCCAAGATGCTGA<mark>GTGAAAGTGGACCCTGGGTGGGCCCGGC</mark> TCCATCCGCAGAGCAGGGCAGTGGGAGGAGACGCCATGACCCCCATCCTCAC<mark>GGTC</mark>CTGATCTGTCTGGGGGAGTTTGAAGAG<mark>GGAGGGGA</mark>GCTTCTAA rccatccgcagagcagagcagtgggagagaggctatgacccccatcctca<mark>cagt</mark>tctgatctgtctcggtgagatttgaagag<mark>ggagaag</mark>agcttcta

#### **Top Skin Tumor-associated sequences**

**C to T change** is known common UV-related mutation



		Avg		Avg Importance
Reference	Altered	Importance	#	. x #
стссстсс	стттсттт	273.136314	6	1638.817886
сттссттссттт	сттсттттт	302.177643	4	1208.710571
ттсс	тттс	83.493270	13	1085.412514
сттс	СТТТ	91.110146	11	1002.211605
тстссттт	тсттттт	161.271838	5	806.359192
тттстттс	тттттт	168.812729	4	675.250916
стсс	сттт	132.571730	5	662.858650
ccggccgg	CCAACCAA	218.585027	3	655.755081
AAATGGGA	AAATAAGA	160.861458	4	643.445831
тттссстс	ттттстс	159.043461	4	636.173843

11.00

#### **Top Lung Tumor-associated Sequences**

**G to T change** is known mutation from benzo(a)pyrene in tobacco

Reference	Altered I	Avg mportance	#	Avg Importance x #
GGGG	GTGG	44.803573	8	358.428585
GGTCGGTCCGTG	GGTAGGTAACTG	159.669815	2	319.339630
GGTG	дтта	38.266541	8	306.132324
GGCCCCAT	GGCCAAAT	89.676956	3	269.030869
TCCCTCCCCAGGTCAT	TCCATCCAAAGGTCAT	126.131210	2	252.262421
GCCTGCCTCGGCCACCCGCG	GCCTGCCTAAGCCACCAGCG	124.771141	2	249.542282
ACGATGATGAGGCCCAGGATCTGT	ACGATGATGAGTCCCATTATGTGT	117.515015	2	235.030029
AGCCAGCCCGAG	AGCCAGCCAGAG	78.167747	3	234.503242
CCTCCCTCCCACTTGCGCTGGGTG	CCTCCCTCCAACTTGAGCTGGGAG	112.450432	2	224.900864
AGAGAGAGGGGCTCACCTGCCGGC	AGAGAGAGTGGCTCACATGCCGGC	110.537506	2	221.075012






#### **Top Renal Clear Cell Carcinoma-associated Sequences**

**Insertions and deletions** are reported to be most common in this cancer

Reference	Altered	Avg mportance	#	Avg Importance x #_
	AAAAAAA	38.893335	13	505.613358
	AAAA	17.492642	23	402.330760
	AAGAAAGAAGAA	37.159491	9	334.435417
CTACCTACCACCACTACCACTAATAG	CTACCTACTACTACCACTATAATAATAATAATAATAATAA	128.056763	2	256.113525
	AAGA	12.586613	19	239.145653
AGATAGATGA	AGAAAGAAGAAAGAAAGAAAGAAAA	107.190369	2	214.380737
AATCAG	AATAATGAATGCACATCATG	102.416496	2	204.832993
CCCTTATCTATCTCCCAG	CCCTTATCTATCTATCTATCTATATATCCCAG	101.835312	2	203.670624
	TATA	9.229853	22	203.056776
CACAGCTTTTTT	CACAGCTTTTTGAATTAAGTTTGAATTAAGTCTAATGTATTAATGTATTTTT	101.356491	2	202.712982

#### Applying Model to Lung Cancer Patient cell-free DNA (cfDNA)



#### **Take-Aways and Future Directions**

#### Some tumor types are more distinguishable than others

Skin cancer is very identifiable and breast cancer is not

**Generating** synthetic reads was a useful alternative

> No real patient DNA used for training

#### CNN can learn mutational signatures

CNN recapitulated some known signatures and the data may contain new insights


#### Model can be used with real sequencing data

Real sequences can be format as input and classified

## For intratumor

Train model to predict by patient for finer grain signature learning





**Top portion of table from** Alexandrov, L.B., Kim, J., Haradhvala, N.J. et al. Nature 578, 94–101 (2020).

#### Instructions for use

In order to use this template, you must credit <u>Slidesgo</u> and <u>Freepik</u> in your final presentation and include links to both websites.

#### You are allowed to:

- Modify this template.
- Use it for both personal and commercial projects.

#### You are not allowed to:

- Sublicense, sell or rent any of Slidesgo Content (or a modified version of Slidesgo Content).
- Distribute Slidesgo Content unless it has been expressly authorized by Slidesgo.
- Include Slidesgo Content in an online or offline database or file.
- Offer Slidesgo templates (or modified versions of Slidesgo templates) for download.
- Acquire the copyright of Slidesgo Content.

For more information about editing slides, please read our FAQs or visit Slidesgo School: https://slidesgo.com/faqs and https://slidesgo.com/slidesgo-school

#### Infographics

You can add and edit some **infographics** to your presentation to present your data in a visual way.

- Choose your favourite infographic and insert it in your presentation using Ctrl C
   + Ctrl V or Cmd C + Cmd V in Mac.
- Select one of the parts and ungroup it by right-clicking and choosing "Ungroup".
- Change the color by clicking on the paint bucket.
- Then resize the element by clicking and dragging one of the square-shaped points of its bounding box (the cursor should look like a double-headed arrow).
   Remember to hold Shift while dragging to keep the proportions.
- Group the elements again by selecting them, right-clicking and choosing "Group".
- Repeat the steps above with the other parts and when you're done editing, copy the end result and paste it into your presentation.
- Remember to choose the "Keep source formatting" option so that it keeps the design. For more info, please visit Slidesgo School.

